Why Agile Therapeutics (AGRX) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- Agile Therapeutics  (AGRX) soared to a 52-week high of $12.53 on Monday after the women's health specialty pharmaceutical company announced the U.S. Patent and Trademark Office issued a new patent for its Skinfusion transdermal delivery device, the contraceptive patch Twirla.

"The granting of this patent further strengthens the patent protection of our proprietary SkinfusionĀ® transdermal technology used in our contraceptive patch, Twirla currently in Phase 3 clinical development," said Agile president and CEO Al Altomari. "The issuance of this patent demonstrates our commitment to protecting our intellectual property in our proprietary transdermal technology and is expected to provide protection into 2028."

The stock was up 43.79% to $11 at 2:09 p.m. More than 1.4 million shares had changed hands, which beat the average volume of 309,870.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AGRX Price Chart

AGRX Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

How a Birth Control Patch Hurt Agile Therapeutics' Stock

Here's Why General Motors Is One of Wednesday's Most Active Stocks

5 Toxic Stocks to Stay Away From This Summer

4 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves Higher: Arcos Dorados and More